SCHEMBL13615295

SCHEMBL13615295

COc1ccccc1S(=O)(=O)Nc1ccc(C(C)(C)C)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
BRD4 O60885 7/20 0.57
BRD1 O95696 1/20 0.57
BRPF1 P55201 1/20 0.57
SLC22A12 Q96S37 1/20 0.55
PKM P14618 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
PTPN2 P17706 2/20 0.50
PTPN1 P18031 2/20 0.50
PTPN5 P54829 2/20 0.50
HSPD1 P10809 1/20 0.50
HSPE1 P61604 1/20 0.50
BRD2 P25440 1/20 0.50
CREBBP Q92793 1/20 0.50
TRIM24 O15164 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13852848 0.86 SLC22A12 (0.54) BRD4BRD1BRPF1SLC22A12PKM
SCHEMBL13615078 0.85 SLC22A12 (0.54) ALDH1A1BRD4SLC22A12PKMSMN1; SMN2
SCHEMBL13615080 0.85 ALDH1A1 (0.77) ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL13629773 0.82 ALDH1A1 (0.57) ALDH1A1NPSR1BRD4BRD1BRPF1
SCHEMBL13615035 0.81 SLC22A12 (0.54) ALDH1A1BRD4SLC22A12SMN1; SMN2MEN1
SCHEMBL13615039 0.80 SLC22A12 (0.65) BRD4SLC22A12
SCHEMBL13615049 0.79 CYTH2 (0.59) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL13852799 0.78 SLC22A12 (0.54) ALDH1A1BRD4SLC22A12SMN1; SMN2MEN1
SCHEMBL13615044 0.77 PKM (0.72) ALDH1A1BRD4PKMSMN1; SMN2MEN1
SCHEMBL13615069 0.77 PGR (0.60) ALDH1A1BRD4PKMSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885NPSR1 3787/4885BRD4 548/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885NPSR1 4042/4885BRD4 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.